Cynaroside alleviates radiation-induced intestinal injury by inhibiting dynamin 2
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.115167 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Jing Xu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The Second Affiliated Hospital and Cancer Institute, Zhejiang University School of Medicine, Hangzhou 310009, China. Hauptthemen laut MEDLINE: Dynamin II, Glucosides, Radiation-Protective Agents, Radiation Injuries, Experimental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Zhejiang Chinese Medical University.
Abstract (Originalsprache)
Cynaroside (Cyn) exhibits unique anti-inflammatory, anti-apoptotic properties and diverse bioactivities; however, its role in mitigating radiation-induced intestinal injury (RIII) remains unclear. This study aimed to investigate the protective effects of Cyn against RIII and explore the underlying mechanisms. C57BL/6 mice were subjected to a single 12 Gy X-ray total abdominal irradiation (TAI) followed by Cyn gavage. Cyn exhibited dose-dependent protection against RIII. Treatment with Cyn improved survival rates, attenuated body weight loss, preserved colon length and intestinal architecture (crypts and villi), reduced radiation-induced inflammatory markers, increased Ki67+ expression, and restore gut microbiota dysbiosis in irradiated mice. Proteomic analysis revealed dynamin 2 as a potential mediator of Cyn's anti-RIII effects. Consistently, dynamin 2 expression was significantly upregulated in colon mucosa specimens from patients who received neoadjuvant radiotherapy. In human intestinal epithelial cells (NCM460), Cyn conferred radioprotection while downregulating dynamin 2 expression. Importantly, treatment with Cyn failed to further increase the protective effects of the dynamin 2 inhibitor dynasore similarly, indicating that dynamin 2 inhibition is essential for Cyn activity. Our findings suggested that Cyn alleviated RIII by suppressing dynamin 2, highlighting its potential as a therapeutic agent for RIII.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, The Second Affiliated Hospital and Cancer Institute, Zhejiang University School of Medicine, Hangzhou 310009, China.
- Research Institute of Chinese Medical Clinical Foundation and Immunology, School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China.
- Nano-Bio-Chem Centre, Suzhou Institute of Nano-Tech and Nano-Bionics, Chinese Academy of Sciences, Suzhou 215123, China.
- State Key Laboratory of Radiation Medicine and Protection, School of Radiation Medicine and Protection, Collaborative Innovation Center of Radiological Medicine of Jiangsu Higher Education Institutions, Soochow Universi…
- Research Institute of Chinese Medical Clinical Foundation and Immunology, School of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China. Electronic address: hzx2015@zcmu.edu.cn.
Förderung
- National Natural Science Foundation of China
- Zhejiang Chinese Medical University
Zitieren
APA
Xu, J., Yang, X., Pu, K., Zhang, Q., Wei, Q., Ma, X., & He, Z. (2025). Cynaroside alleviates radiation-induced intestinal injury by inhibiting dynamin 2. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.115167
Vancouver
Xu J, Yang X, Pu K, Zhang Q, Wei Q, Ma X, et al. Cynaroside alleviates radiation-induced intestinal injury by inhibiting dynamin 2. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.115167
BibTeX
@article{Xu2025,
author = {Xu, Jing and Yang, Xueting and Pu, Kefeng and Zhang, Qingyi and Wei, Qichun and Ma, Xiaochuan and He, Zhixing},
title = {Cynaroside alleviates radiation-induced intestinal injury by inhibiting dynamin 2},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.115167}
}
EUVIMED